The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IL33-ST2 axis as a diagnostic and therapeutic biomarker in nivolumab therapy for advanced gastric cancer.
 
Chie Kudo-Saito
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hirokazu Shoji
Research Funding - Amgen (Inst); Astellas Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Imazeki
No Relationships to Disclose
 
Kengo Nagashima
Consulting or Advisory Role - Kowa; Lilly (Inst); Senju Pharmaceutical; Toray Industries
 
Kai Tsugaru
No Relationships to Disclose
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takeshi Kawakami
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yusuke Amanuma
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Naohiro Okano
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yukiya Narita
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Ono Pharmaceutical (Inst)
 
Yoshiyuki Yamamoto
Honoraria - Chugai Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Taiho, Sanofi, Yakult, Nihon Servier, Lilly, Asahi Kasei Parma
 
Rika Kizawa
No Relationships to Disclose
 
Kazunori Aoki
Research Funding - Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, Daiichi Sankyo, and Chiome Bioscience
 
Kei Muro
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International (Inst); PRA Health Sciences (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)